At ASCO 2020 meeting, the new final survival results of the SPARTAN study were reported. When we look at overall survival in SPARTAN, the use of apalutamideprolongs survival from 60 months to 74 months – that is a 14-month survival advantage, with a hazard ratioof 0.78. Earlier reports have shown significant advantages in reduction of metastasis development rates and the time to symptomatic regression.

CheckMate 9LA is the second trial in a row of trials investigating the role of immunotherapy combinations in patients with non-small cell lung cancer (NSCLC). At the preplanned interim analysis after 8.1 months, overall survival was significantly prolonged with the combination of ipilimumab (IPI) and nivolumab (NIVO) and chemo vs chemo alone as front-line therapy in unselected patients with advanced NSCLC at all PD-L1 levels.

Watch the key takeaways in prostate cancer from ASCO20 Virtual by Professor Eric Small.

Do patients with non-metastatic castration-resistant prostate cancer exist or do they all have metastases if submitted to a PET scan? See Eric J. Small’s MEDtalk and hear his thoughts on the matter.

Professor Martin Reck explaining the background for CheckMate 9LA-study and the effect of the combination of nivolumab and ipilimumab + 2 cycles of chemotherapy as first-line treatment of stage IV/recurrent non-small cell lung cancer.

In this MEDtalk, Eric J. Small, MD and principal investigator of the SPARTAN study describes what characterizes the group of patients with non-metastatic castration-resistant prostate cancer.

#Siste magasin

Onkologi / Hematologi

Nr. 2 • mars 2020
10. Årgang
  • Pancreas cancer
  • Meningeom
  • Livmorhalskreft

Tweets by ASCO